Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | INBX |
---|---|---|
09:32 ET | 532 | 15.18 |
09:50 ET | 1100 | 15.17 |
09:56 ET | 100 | 15.505 |
10:21 ET | 8670 | 15.48 |
10:26 ET | 500 | 15.34 |
10:28 ET | 286 | 15.45 |
10:32 ET | 473 | 15.4 |
10:33 ET | 497 | 15.37 |
10:35 ET | 400 | 15.39 |
10:37 ET | 494 | 15.39 |
10:39 ET | 1257 | 15.45 |
10:46 ET | 200 | 15.51 |
10:48 ET | 200 | 15.49 |
10:51 ET | 900 | 15.45 |
10:53 ET | 1200 | 15.49 |
10:55 ET | 100 | 15.45 |
10:57 ET | 134 | 15.4 |
11:36 ET | 836 | 15.4938 |
12:02 ET | 200 | 15.44 |
12:20 ET | 372 | 15.32 |
12:30 ET | 2450 | 15.27 |
12:32 ET | 1500 | 15.29 |
12:41 ET | 635 | 15.325 |
12:43 ET | 200 | 15.315 |
12:45 ET | 1300 | 15.35 |
12:48 ET | 3211 | 15.285 |
12:52 ET | 2035 | 15.24 |
12:54 ET | 100 | 15.25 |
12:56 ET | 500 | 15.28 |
12:57 ET | 300 | 15.24 |
01:01 ET | 325 | 15.26 |
01:08 ET | 300 | 15.31 |
01:14 ET | 300 | 15.27 |
01:30 ET | 2788 | 15.31 |
01:32 ET | 100 | 15.37 |
01:35 ET | 860 | 15.315 |
01:39 ET | 100 | 15.35 |
01:42 ET | 640 | 15.3 |
01:46 ET | 557 | 15.27 |
01:48 ET | 600 | 15.25 |
01:51 ET | 1100 | 15.2466 |
02:04 ET | 3421 | 15.18 |
02:27 ET | 100 | 15.2 |
03:05 ET | 670 | 15.2699 |
03:12 ET | 100 | 15.21 |
03:21 ET | 237 | 15.23 |
03:30 ET | 729 | 15.14 |
03:32 ET | 100 | 15.16 |
03:34 ET | 932 | 15.15 |
03:36 ET | 304 | 15.14 |
03:41 ET | 986 | 15.09 |
03:43 ET | 400 | 15.09 |
03:48 ET | 300 | 15.06 |
03:50 ET | 557 | 15.09 |
03:57 ET | 949 | 15.09 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Inhibrx Biosciences Inc | 218.4M | -2.8x | --- |
Century Therapeutics Inc | 212.9M | -1.2x | --- |
Skye Bioscience Inc | 221.2M | -1.8x | --- |
Zura Bio Ltd | 215.3M | -2.1x | --- |
ESSA Pharma Inc | 215.2M | -7.7x | --- |
Solid Biosciences Inc | 222.6M | -1.5x | --- |
Inhibrx Biosciences, Inc. is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. The Company’s clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106. INBRX-109 is a tetravalent agonist of death receptor 5 (DR5) that is designed with its proprietary single domain antibody, or sdAb, platform to drive cancer-selective programmed cell death and to maximize potency while minimizing on-target liver toxicity arising from hepatocyte apoptosis. INBRX-106 is a hexavalent OX40 agonist, being investigated as a single agent and in combination with Keytruda, a PD-1 blocking checkpoint inhibitor, in patients with locally advanced or metastatic solid tumors. INBRX-106 is a precisely engineered hexavalent sdAb-based therapeutic candidate targeting OX40, designed to be an optimized agonist of this co-stimulatory receptor.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $218.4M |
---|---|
Revenue (TTM) | $1.8M |
Shares Outstanding | 14.5M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-5.35 |
Book Value | $0.92 |
P/E Ratio | -2.8x |
Price/Sales (TTM) | 122.5 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -13,980.93% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.